Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD
Aliment Pharmacol Ther
.
2021 May;53(9):1038-1039.
doi: 10.1111/apt.16325.
Authors
Ashish Srinivasan
1
2
3
,
Craig Haifer
4
5
,
Lena Thin
6
7
Affiliations
1
Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.
2
Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
3
Monash University, Melbourne, VIC, Australia.
4
Department of Gastroenterology, St Vincent's Hospital, Sydney, NSW, Australia.
5
The University of Sydney, Sydney, NSW, Australia.
6
Department of Gastroenterology, Fiona Stanley Hospital, Perth, WA, Australia.
7
The University of Western Australia, Perth, WA, Australia.
PMID:
33831242
DOI:
10.1111/apt.16325
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal
Biosimilar Pharmaceuticals*
Humans
Inflammatory Bowel Diseases* / therapy
Infliximab
Prospective Studies
Substances
Antibodies, Monoclonal
Biosimilar Pharmaceuticals
CT-P13
Infliximab